Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study (Exact Sciences)

Exact Sciences has begun enrolling patients in its Multi-Cancer Early Detection (MCED) Falcon Registry study, aimed at evaluating the clinical performance and impact of its MCED test. The study will involve up to 25,000 patients across multiple sites, including Baylor Scott & White and Endeavor Health, to assess early cancer detection’s effectiveness and its potential to transform cancer care. The data gathered will support the test’s future development and regulatory discussions, aligning with the broader goal of reducing cancer mortality.